The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Abstract
Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.Methods We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative risks (RRs) and 95% CIs for each outcome. We did subgroup analyses to assess whether differences in patient and trial characteristics affected outcomes. We used a random-effects model to compare pooled outcomes and tested for heterogeneity.Findings 42,411 participants received a new oral anticoagulant and 29,272 participants received warfarin. New oral anticoagulants significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0·81, 95% CI 0·73-0·91; p<0·0001), mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38-0·64; p<0·0001). New oral anticoagulants also significantly reduced all-cause mortality (0·90, 0·85-0·95; p=0·0003) and intracranial haemorrhage (0·48, 0·39-0·59; p<0·0001), but increased gastrointestinal bleeding (1·25, 1·01-1·55; p=0·04). We noted no heterogeneity for stroke or systemic embolic events in important subgroups, but there was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66% or more (0·69, 0·59-0·81 vs 0·93, 0·76-1·13; p for interaction 0·022). Low-dose new oral anticoagulant regimens showed similar overall reductions in stroke or systemic embolic events to warfarin (1·03, 0·84-1·27; p=0·74), and a more favourable bleeding profile (0·65, 0·43-1·00; p=0·05), but significantly more ischaemic strokes (1·28, 1·02-1·60; p=0·045).Interpretation This meta-analysis is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemic embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk-benefit profile, with significant reductions in stroke, intracranial haemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. The relative efficacy and safety of new oral anticoagulants was consistent across a wide range of patients. Our findings offer clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.Funding None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) markedly reduces stroke and mortality in AF patients.38,39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“and hence there is strong evidence that patients with a CHA 2 DS 2 -VASc risk score of 2 or more in men, and 3 or more in women benefit from OAC.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke, 38,39,42,194,201,329,351,352”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Mortality was 10% lower in patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85-0.95;P = 0.0003) and intracranial haemorrhage was halved (RR 0.48; 95% CI 0.39-0.59;P < 0.0001), while gastrointestinal bleeding events were more frequent (RR 1.25; 95% CI 1.01-1.55;P = 0.04).39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“NOACs in these dosages significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73-0.91;P < 0.0001), mainly driven by a reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38-0.64;P < 0.0001).”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“A meta-analysis 39 based on the highdose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a NOAC and 29,272 receiving warfarin.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Good data are available to support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged Study), 362 the NOAC trials, 39 and from analyses in elderly Americans (Medicare).396”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Cited by
Sorted by citations
Items 401–500 of 1,004
Conen, D., Alonso‐Coello, P., Douketis, J. D., Chan, M. T. V., Kurz, A. M., Sigamani, A., Parlow, J. L., Wang, C. Y., Villar, J. C., Srinathan, S., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz431 · Cited by 79
Factor XI and factor XII as targets for new anticoagulants
Weitz, J. I. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30363-2 · Cited by 78
Andò, G., & Capranzano, P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.303 · Cited by 79
Lee, S., Lee, Y. S., Park, J.-S., Cha, M., Kim, T., Park, J., Park, J., Lee, J., Kang, K., Shim, J., et al. (2019) · Yonsei Medical Journal · doi:10.3349/ymj.2019.60.3.277 · Cited by 78
Boriani, G., Laroche, C., Diemberger, I., Fantecchi, E., Popescu, M. I., Rasmussen, L. H., Dan, G., Kalarus, Z. F., Tavazzi, L., Maggioni, A. P., et al. (2016) · EP Europace · doi:10.1093/europace/euv390 · Cited by 78
Direct oral anticoagulants versus warfarin: is new always better than the old?
Burn, J., & Pirmohamed, M. (2018) · Open Heart · doi:10.1136/openhrt-2017-000712 · Cited by 79
New anticoagulants: Moving beyond the direct oral anticoagulants
Fredenburgh, J. C., & Weitz, J. I. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15126 · Cited by 81
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 76
Shen, Y., Zhang, W., Xie, Y., Li, A., Wang, X., Chen, X., Liu, Q., Wang, Q., Zhang, G., Liu, Q., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121208 · Cited by 76
Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation
Lópes, R. D., Granger, C. B., WOJDYLA, D. M., McIntyre, W. F., Alings, M., Mani, T., Ramasundarahettige, C. F., Rivard, L., Atar, D., Birnie, D. H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.002 · Cited by 76
Stacy, Z. A., Call, W. B., Hartmann, A. P., Peters, G. L., & Richter, S. K. (2016) · Cardiology and Therapy · doi:10.1007/s40119-016-0058-2 · Cited by 77
Laparoscopic cholecystectomy for the various types of gallbladder inflammation: a prospective trial.
Eldar, S., Sabo, E., Nash, E., Abrahamson, J., & Matter, I. (1998) · PubMed · Cited by 75
Evaluation and management of Non-variceal upper gastrointestinal bleeding
Samuel, R. E., Bilal, M., Tayyem, O., & Guturu, P. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2018.02.003 · Cited by 80
Chu, M., Zhang, S., Gong, J., Yang, S., Yang, G., Sun, X., Wu, D., Xia, Y., Jiao, J., Peng, X., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03511-2 · Cited by 75
Giugliano, R. P., Ruff, C. T., Wiviott, S. D., Nordio, F., Murphy, S. A., Kappelhof, J. A. N., Shi, M., Mercuri, M. F., Antman, E. M., & Braunwald, E. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.028 · Cited by 75
Patti, G., Gioia, G. D., Cavallari, I., & Nenna, A. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2876 · Cited by 76
Costa, O. S., Connolly, S. J., Sharma, M., Beyer‐Westendorf, J., Christoph, M. J., Lovelace, B., & Coleman, C. I. (2022) · Critical Care · doi:10.1186/s13054-022-04043-8 · Cited by 74
Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation
Freedman, B., Martínez, C., Katholing, A., & Rietbrock, S. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0393 · Cited by 74
Jung, H., Yang, P., Jang, E., Yu, H. T., Kim, T., Uhm, J., Kim, J., Pak, H., Lee, M., Joung, B., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.11.009 · Cited by 74
Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
on behalf of Grupo de trabajo de Riesgo vascular de la, S. E. M. I., Fernández, C. S., Formiga, F., Camafort, M., Rodrigo, J. M. C., Díez‐Manglano, J., Reino, A. P., Tiberio, G., & Mostaza, J. M. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0137-7 · Cited by 75
Left atrial appendage occlusion: rationale, evidence, devices, and patient selection
Piccini, J. P., Sievert, H., & Patel, M. R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw330 · Cited by 73
Silverio, A., Maio, M. D., Prota, C., Angelis, E. D., Radano, I., Citro, R., Carrizzo, A., Ciccarelli, M., Vecchione, C., Capodanno, D., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz073 · Cited by 73
Randomized Trials Versus Common Sense and Clinical Observation
Fanaroff, A. C., Califf, R. M., Harrington, R. A., Granger, C. B., McMurray, J. J. V., Patel, M. R., Bhatt, D. L., Windecker, S., Hernandez, A. F., Gibson, C. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.069 · Cited by 77
Factor XI inhibitors: cardiovascular perspectives
Caterina, R. D., Prisco, D., & Eikelboom, J. W. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac464 · Cited by 79
Salman, R. A., Stephen, J., Tierney, J. F., Lewis, S. C., Newby, D. E., Parry‐Jones, A., White, P., Connolly, S. J., Benavente, O., Dowlatshahi, D. D., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00315-0 · Cited by 75
Jabbour, G., Nolin-Lapalme, A., Tastet, O., Corbin, D., Jordà, P., Sowa, A., Delfrate, J., Busseuil, D., Hussin, J., Dubé, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae595 · Cited by 85
Anticoagulation Resumption After Intracerebral Hemorrhage
Li, Y., & Lip, G. Y. H. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0733-y · Cited by 73
Bertaglia, E., Blank, B., Blomström‐Lundqvist, C., Brandes, A., Cabanelas, N., Dan, G. A., Dichtl, W., Goette, A., de Groot, J. R., Lubiński, A., et al. (2019) · EP Europace · doi:10.1093/europace/euz172 · Cited by 72
Novel oral anticoagulants and reversal agents: Considerations for clinical development
Sarich, T. C., Seltzer, J. H., Berkowitz, S. D., Costin, J. C., Curnutte, J. T., Gibson, C. M., Hoffman, M., Kaminskas, E., Krucoff, M. W., Levy, J. H., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.010 · Cited by 75
Shields, A. M., & Lip, G. Y. H. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12360 · Cited by 72
Oral anticoagulation: a critique of recent advances and controversies
Pirmohamed, M., Kamali, F., Daly, A. K., & Wadelius, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.01.003 · Cited by 72
Prevalence of Left Atrial Thrombus Detection by Transesophageal Echocardiography
Frenkel, D., D’Amato, S. A., Al‐Kazaz, M., Markowitz, S. M., Liu, C. F., Thomas, G., Ip, J. E., Sharma, S., Yang, H., Singh, P., et al. (2016) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2016.01.004 · Cited by 72
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · Journal of Arrhythmia · doi:10.1002/joa3.13082 · Cited by 76
Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban
MORISHIMA, Y., & Kamisato, C. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpq2njd3pxftug · Cited by 71
Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation
Ruff, C. T., Giugliano, R. P., D, E. B. M., Murphy, S. A., Brown, K. S., Jarolı́m, P., Mercuri, M. F., Antman, E. M., & Morrow, D. A. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3311 · Cited by 71
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants
Touzé, E., Gruel, Y., Gouin‐Thibault, I., de Maistre, E., Susen, S., Siè, P., & Derex, L. (2018) · European Journal of Neurology · doi:10.1111/ene.13582 · Cited by 71
Abrignani, M. G., Gatta, L., Gabrielli, D., Milazzo, G., Francesco, V. D., Luca, L. D., Francese, M., Imazio, M., Riccio, E., Rossini, R., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.11.014 · Cited by 78
Schaefer, J. K., Errickson, J., Li, Y., Kong, X., Alexandris-Souphis, T., Ali, M. A., DeCamillo, D., Haymart, B., Kaatz, S., Kline-Rogers, E. M., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.1197 · Cited by 74
Hoeltzenbein, M., Beck, E., Meixner, K., Schaefer, C., & Kreutz, R. H. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0893-5 · Cited by 71
Cerebral Ischemia in Patients on Direct Oral Anticoagulants
Macha, K., Marsch, A., Siedler, G., Breuer, L., Strasser, E. F., Engelhorn, T., Schwab, S., & Kallmünzer, B. (2019) · Stroke · doi:10.1161/strokeaha.118.023877 · Cited by 71
Brown, J. D., Shewale, A. R., & Talbert, J. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.11.1319 · Cited by 70
Benzimra, M., Bonnamour, B., Duracinský, M., Lalanne, C., Aubert, J.-P., Chassany, O., Aubin-Auger, I., & Mahé, I. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s131158 · Cited by 74
Neuroimaging and clinical outcomes of oral anticoagulant–associated intracerebral hemorrhage
Tsivgoulis, G. K., Wilson, D., Katsanos, A. H., Sargento‐Freitas, J., Marques‐Matos, C., Azevedo, E. I., Adachi, T., von der Brelie, C., Aizawa, Y., Abe, H., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25342 · Cited by 70
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Chaudhary, R., Sharma, T., Garg, J., Sukhi, A., Bliden, K. P., Tantry, U. S., Turagam, M. K., Lakkireddy, D., & Gurbel, P. A. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01954-2 · Cited by 72
Lettino, M., Mascherbauer, J., Nordaby, M., Ziegler, A., Collet, J., Dérumeaux, G., Hohnloser, S. H., Leclercq, C., O’Neill, D. E., Visseren, F. L. J., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac033 · Cited by 82
Gil-García, C.-A., Flores-Álvarez, E., Cebrian-Garcia, R., Mendoza-Lopez, A.-C., González-Hermosillo, L.-M., Garcia-Blanco, M.-D.-C., & Roldán-Valadéz, E. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101328 · Cited by 72
Williams, B. A., Honushefsky, A. M., & Berger, P. B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.08.014 · Cited by 69
Zeeshan, M., Jehan, F., O’Keeffe, T., Khan, M., Zakaria, E. R., Hamidi, M., Gries, L. M., Kulvatunyou, N., & Joseph, B. A. (2018) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001995 · Cited by 71
Atrial Fibrillation, Type 2 Diabetes, and Non–Vitamin K Antagonist Oral Anticoagulants
Plitt, A., McGuire, D. K., & Giugliano, R. P. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5224 · Cited by 70
Research Priorities in Atrial Fibrillation Screening
Benjamin, E. J., Go, A. S., Desvigne-Nickens, P. M., Anderson, C. D., Casadei, B., Chen, L. Y., Crijns, H. J. G. M., Freedman, B., Hills, M. T., Healey, J. S., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.047633 · Cited by 71
Bassand, J., Virdone, S., Badoz, M., Verheugt, F. W. A., Camm, A. J., Cools, F. J. S., Fox, K. A. A., Goldhaber, S. Z., Goto, S., Haas, S. K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003560 · Cited by 72
Mesnier, J., Guillén, P. L. C., Freixa, X., Flores‐Umanzor, E., Trinh, K. H., O’Hara, G. E., & Rodés‐Cabau, J. (2023) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.122.012812 · Cited by 69
Steinberg, B. A., Blanco, R. G., Ollis, D. M., Kim, S., Holmes, D. N., Kowey, P. R., Fonarow, G. C., Ansell, J., Gersh, B. J., Go, A. S., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.04.005 · Cited by 71
Chen, N., Lutsey, P. L., MacLehose, R. F., Claxton, J. S., Norby, F. L., Chamberlain, A. M., Bengtson, L. G. S., O’Neal, W. T., Chen, L. Y., & Alonso, Á. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009561 · Cited by 67
TAVR Patients Requiring Anticoagulation
Didier, R. J., Lhermusier, T., Auffret, V., Eltchaninoff, H., Breton, H., Cayla, G., Commeau, P., Collet, J., Cuisset, T., Dumonteil, N., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.05.025 · Cited by 71
Schutgens, R. E. G., Jiménez‐Yuste, V., Escobar, M. A., Falanga, A., Gigante, B., Klamroth, R., Lassila, R., Leebeek, F. W. G., Makris, M., Owaidah, T. M., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000900 · Cited by 72
Targeting factor XI and factor XIa to prevent thrombosis
Gailani, D., & Gruber, A. (2023) · Blood · doi:10.1182/blood.2023020722 · Cited by 68
Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned?
Hankey, G. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0480-9 · Cited by 67
New oral anticoagulants: a practical guide for physicians
Hinojar, R., Jiménez-Natcher, J. J., Fernández‐Golfín, C., & Zamorano, J. L. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv002 · Cited by 68
Desteghe, L., Vijgen, J. M., Koopman, P., Dilling-Boer, D. M., Schurmans, J., Dendale, P., & Heidbüchel, H. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx762 · Cited by 70
Dissection of Cervical and Cerebral Arteries
Engelter, S. T., Traenka, C., & Lyrer, P. A. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0769-3 · Cited by 71
Stroke Prevention in Nonvalvular Atrial Fibrillation
Alkhouli, M. A., Noseworthy, P. A., Rihal, C. S., & Holmes, D. R. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.013 · Cited by 70
Tereshchenko, L. G., Henrikson, C. A., Cigarroa, J. E., & Steinberg, J. S. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003206 · Cited by 69
Okumura, Y., Yokoyama, K., Matsumoto, N., Tachibana, E., Kuronuma, K., Oiwa, K., Matsumoto, M., Kojima, T., Hanada, S., Nomoto, K., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0535 · Cited by 67
Menichelli, D., Sole, F. D., Rocco, A. D., Farcomeni, A., Vestri, A., Violi, F., Pignatelli, P., Lip, G. Y. H., & Pastori, D. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab002 · Cited by 67
Gorog, D. A., Gue, Y. X., Chao, T., Fauchier, L., Ferreiro, J. L., Huber, K., Konstantinides, S., Lane, D. A., Marín, F. R., Oldgren, J., et al. (2022) · EP Europace · doi:10.1093/europace/euac020 · Cited by 70
Potpara, T., Grygier, M., Hæusler, K. G., Nielsen‐Kudsk, J. E., Berti, S. L., Genovesi, S., Marijon, É., Bovéda, S., Tzikas, A., Boriani, G., et al. (2024) · EP Europace · doi:10.1093/europace/euae035 · Cited by 78
An update on atrial fibrillation in 2014: From pathophysiology to treatment
Ferrari, R., Bertini, M., Blomström‐Lundqvist, C., Dobrev, D., Kirchhof, P. F., Pappone, C., Ravens, U., Tamargo, J. L., Tavazzi, L., & Vicedomini, G. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.089 · Cited by 67
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
Vanassche, T., Hirsh, J., Ginsberg, J. S., & Eikelboom, J. W. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0346 · Cited by 66
Risk of stroke in congestive heart failure with and without atrial fibrillation
Kang, S., Kim, J., Park, J. J., Oh, I., Yoon, C., Kim, H. J., Kim, K., & Choi, D. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.056 · Cited by 67
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding
Boriani, G., Corradini, P., Cuneo, A., Falanga, A., Foà, R., Gaïdano, G., Ghia, P., Martelli, M., Marasca, R., Massaia, M., et al. (2018) · Hematological Oncology · doi:10.1002/hon.2503 · Cited by 68
Chokesuwattanaskul, R., Thongprayoon, C., Tanawuttiwat, T., Kaewput, W., Pachariyanon, P., & Cheungpasitporn, W. (2018) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13331 · Cited by 69
Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients
Li, Y., Lee, S., Choi, E., & Lip, G. Y. H. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0190 · Cited by 68
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
Pollack, C. V., & Weitz, J. I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0222 · Cited by 65
Geis, N., Kiriakou, C., Chorianopoulos, E., Uhlmann, L., Katus, H., & Bekeredjian, R. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1247-x · Cited by 62
Wang, C., Wu, V. C., Kuo, C., Chu, P., Tseng, H., Wen, M., & Chang, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009263 · Cited by 64
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation
Ganse, E. H. V., Danchin, N., Mahé, I., Hanon, O., Jacoud, F., Nolin, M., Dalon, F., Lefèvre, C., Cotté, F.-E., Gollety, S., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.028825 · Cited by 66
Heavy menstrual bleeding on rivaroxaban
Ferreira, M., Barsam, S. J., Patel, J. P., Czuprynska, J., Roberts, L. N., Patel, R., & Arya, R. (2015) · British Journal of Haematology · doi:10.1111/bjh.13583 · Cited by 66
on behalf of the APACHE-AF investigators, van Nieuwenhuizen, K. M., van der Worp, H. B., Algra, A., Kappelle, L. J., Rinkel, G. J. E., Gelder, I. C. V., Schutgens, R. E. G., & Klijn, C. J. M. (2015) · Trials · doi:10.1186/s13063-015-0898-4 · Cited by 68
Wilson, D., Ambler, G., Banerjee, G., Shakeshaft, C., Cohen, H., Yousry, T. A., Salman, R. A., Lip, G. Y. H., Houlden, H., Brown, M. M., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318890 · Cited by 67
Thrombolysis In Myocardial Infarction (TIMI) Study Group
Sabatine, M. S., & Braunwald, E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.060 · Cited by 70
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis
Galli, M., Laborante, R., Ortega‐Paz, L., Franchi, F., Rollini, F., D’Amario, D., Capodanno, D., Tremoli, E., Gibson, C. M., Mehran, R., et al. (2023) · Thrombosis and Haemostasis · doi:10.1055/a-2043-0346 · Cited by 69
Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants
Dhakal, P., Rayamajhi, S., Verma, V., Gundabolu, K., & Bhatt, V. R. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616675970 · Cited by 66
Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants
Albaladejo, P., Samama, C. M., Siè, P., Kauffmann, S., Mémier, V., Suchon, P., Viallon, A., David, J., Gruel, Y., Bellamy, L., et al. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001631 · Cited by 66
Hobbs, R. F., Taylor, C. J., Geersing, G. J., Rutten, F. H., Brouwer, J. R., & on behalf of the European Primary Care Cardiovascular Society (EPCCS) SPAF working group (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315571890 · Cited by 67
Deitelzweig, S. B., Luo, X., Gupta, K. B., Trocio, J. N., Mardekian, J., Curtice, T. G., Lingohr-Smith, M., Menges, B., & Lin, J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1334638 · Cited by 67
Maura, G., Billionnet, C., Drouin, J., Weill, A., Neumann, A., & Pariente, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026645 · Cited by 67
Pharmacogenomics for Primary Care: An Overview
Rollinson, V., Turner, R. M., & Pirmohamed, M. (2020) · Genes · doi:10.3390/genes11111337 · Cited by 64
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-024-01771-5 · Cited by 66
Sahay, S., y, L. N.-F., Rodés‐Cabau, J., Jiménez‐Quevedo, P., Salinas, P., Biagioni, C., Nuñez-Gil, I. J., Gonzalo, N., de Agustín, J. A., Trigo, M. D., et al. (2016) · Heart · doi:10.1136/heartjnl-2016-309782 · Cited by 64
Steinberg, B. A., Shrader, P., Thomas, L. E., Ansell, J., Fonarow, G. C., Gersh, B. J., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., O'Brien, E. C., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.024 · Cited by 65
Global Prospective Safety Analysis of Rivaroxaban
Kirchhof, P. F., Radaideh, G. A., Kim, Y., Lanas, F. T., Haas, S. K., Amarenco, P., Turpie, A. G. G., Bach, M., Lambelet, M., Hess, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.058 · Cited by 64
Atrial fibrillation detected initially during acute medical illness: A systematic review
McIntyre, W. F., Um, K. J., Cheung, C. C., Belley‐Côté, E. P., Dingwall, O., Devereaux, P. J., Wong, J. A., Conen, D., Whitlock, R. P., Connolly, S. J., et al. (2018) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872618799748 · Cited by 64
Little, D. H. W., Chai‐Adisaksopha, C., Hillis, C., Witt, D. M., Monréal, M., Crowther, M. A., & Siegal, D. M. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.01.020 · Cited by 65
Dias, J. D., Lopez-Espina, C. G., Ippolito, J., Hsiao, L. H., Zaman, F., Muresan, A. A., Thomas, S. G., Walsh, M. M., Jones, A. J., Grisoli, A., et al. (2019) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002357 · Cited by 64
Slot, K. B., & Berge, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008980.pub3 · Cited by 68
Pastori, D., Pignatelli, P., Saliola, M., Carnevale, R., Vicario, T., Ben, M. D., Cangemi, R., Barillà, F., Lip, G. Y. H., & Violi, F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.054 · Cited by 63
Risk of gastrointestinal bleeding during anticoagulant treatment
Lanas-Gimeno, A., & Lanas, A. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1325870 · Cited by 65
Yu, A., Malo, S., Svenson, L. W., Wilton, S. B., & Hill, M. D. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007129 · Cited by 64
Huttner, H. B., Gerner, S. T., Kuramatsu, J. B., Connolly, S. J., Beyer‐Westendorf, J., Demchuk, A. M., Middeldorp, S., Zotova, E., Altevers, J., Andersohn, F., et al. (2021) · Stroke · doi:10.1161/strokeaha.121.034572 · Cited by 66
Metadata
- Authors
- Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Thomas Jefferson University (US)
- St George's, University of London (GB)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Carmel Medical Center (IL)
- Cardiovascular Institute Hospital (JP)
- Corresponding author
- Ruff, Christian T
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9921
- Pages
- 955-962
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2152623033
- Cited by
- 5,051
- References
- 45
- Citations by year
- 2026: 249 · 2025: 310 · 2024: 399 · 2023: 426 · 2022: 410 · 2021: 490 · 2020: 521 · 2019: 462 · 2018: 456 · 2017: 447 · 2016: 406 · 2015: 318 · 2014: 139
- FWCI
- 49.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- direct oral anticoagulants, warfarin, atrial fibrillation, stroke prevention, systemic embolism, hemorrhagic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause mortality, subgroup analysis, factor Xa inhibitors, dabigatran, rivaroxaban, apixaban
- MeSH terms
- Administration, Oral, Anticoagulants, Atrial Fibrillation, Embolism, Humans, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
